Questions across 2 calls

Narayan Singh

Navanand Securities

Neuland Laboratories Limited

Neuland Laboratories Limited CC-Dec23.pdf · 2024-02-09

So congratulations on a good set of results, sir. I just have one question. So there are some news flow around about this KarXT and Karuna Therapeutics takeover by Bristol Myers and so on. The question is this molecule considered as near commercialization molecule or it's already under commercialization molecule, sir? Just for my understanding, to understand.

Thanks for the clarity here. I understand that you don't want to disclose any more information. But if you answer my one more follow-up question about what happens if the biotech companies are taken by big pharma, and we are hoping that the company will really benefit from this kind of acquisitions. Thank you, sir. And all the best for the future.

Zen Technologies Limited

Zen Technologies Limited CC-Dec23.pdf · 2024-01-29

In the beginning, I wanted to ask a question about the QIP, but after so many participants asked the similar questions, I got a little bit of clarity and the purpose of QIP and let's say this is just enabler. So still I want to raise this question to you. So when I first look at your past history, you bought the shares from the market to have it for ESOP. So that clearly showed me how much you value the capital of the company and you are not really willing to let go the equity so easily of your Company. So, I still think that if you're talking about so much prospects for the company in the next three years, I just wish that whatever acquisition we make is really, really adding big value to the company and shareholders. That's all I have. I don't have any other question actually.